Skip to content

Role Of Trikatu Kajjali Tablet And Trimada Kajjali Tablet In Liver Disease In Non Alcoholic Persons.

Efficacy of Trikatu Kajjali and Trimada Kajjali Tablet With Lifestyle Modification in Management of Yakrit Vikara (Non Alcoholic Fatty Liver Disease)- An Open Labeled Randomized Comparative Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/02/023426
Enrollment
30
Registered
2020-02-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Trikatu Kajjali: Tablet Dose Tab(250mg)Twice a day Route of Administration Oral Anupana Lukewarm Water Duration 2 Months Control Intervention1: Trimada Kajjali: Tablet Dose Tab(250mg)

Sponsors

Director IPGT and RA GAU Jamnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either sex of age group, above 25yrs and below 60yrs. USG findings suggestive of NAFLD grade I , II &III Both freshly detected and previously diagnosed cases of NAFLD

Exclusion criteria

Exclusion criteria: Patient aged below 25 years and above 60 years, pregnant ladies Patients with uncontrolled diabetes or hypertension , Patients with complications of Metabolic syndrome like Cerebrovascular accident, Myocardial Infarction, Chronic Kidney disease Patients consuming hepatotoxic medicines, alcohol or other narcotic substances Patients suffering from Cirrhosis, Ascites, variceal hemorrhage, coagulopathy, hepato renal syndrome Patients having history of viral hepatitis, auto immune liver diseases ( Primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis), metabolic disorders ( Wilsonâ??s disease, haemochromatosis) Patients suffering from HIV, TB other infectious diseases, malignancies, major psychiatric problems or any other serious illnesses.

Design outcomes

Primary

MeasureTime frame
Improvement Will be Assessed on the Basis of Relief found in Cardinal Symptoms of Disease Progress in the Signs and Symptoms based on the Standard Pattern will be Applied Before and After treatmentTimepoint: 2 Months

Secondary

MeasureTime frame
Improvement will be Assessed on the Basis of Relief found in Cardinal Symptoms of Disease Progress in the Signs and Symptoms based on the Standard Pattern will be Applied Before and After TreatmentTimepoint: 2 Months

Countries

India

Contacts

Public ContactDr Mandip Goyal

IPGT AND RA

kaurmandip22@yahoo.com9427572306

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026